The roadmap describes the actions needed to
achieve the three development goals for TB
vaccines set by the WHO:
1. A safe, effective and affordable TB vaccine
for adolescents and adults.
2. An affordable TB vaccine for neonates and
infants with improved safety and efficacy.
3. A therapeutic v...accine to improve TB
treatment outcomes
more
This Study presents the key results of a research that analyses the implications of an ambitious agroecological transition across Europe, following the TYFA scenario. Published in 2018, what it proposes by 2050 is fully aligned with the objectives that the European Farm to Fork and Biodiversity stra...tegies aim to achieve by 2030, in particular regarding the decrease in pesticides, nitrogen, and antibiotics on the supply side, and the transition towards more plant-based diets on the demand side. Using a world biomass balance model (GlobAgri-AgT), the impact of the TYFA scenario in the EU on world land use, the EU physical trade balance, the provision of calories and global food security is analysed in addition to key policy levers to spur the transition.
more
The KMC implementation strategy targets a broad audience. These include policy-makers and programme managers at national, regional and local levels, government and nongovernmental organizations working in the area of maternal and newborn care, global and national professional associations, public an...d private hospital management at all levels of care, and facility- and community-based maternal and infant care providers.
more
This Indicator-Based Pharmacovigilance Assessment Tool (IPAT) was developed as a comprehensive performance metric for pharmacovigilance and medicine safety systems.
22 July 2022. This document summarizes current WHO guidance for public health surveillance of coronavirus disease 2019 (COVID-19) in humans caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Навчальні та методичні модулі ініціативи ВООЗ QualityRights було розроблено з метою покращення знань, навичок та розуміння ключових зацікавлених сторін про те, як сприя...и дотриманню прав людини осіб з інвалідністю внаслідок психосоціальних, інтелектуальних та когнітивних порушень, а також задля підви¬щення якості послуг і видів підтримки, які надаються в охороні психічного здоров’я та пов’язаних сферах, у відповідності з міжнародними стандартами прав людини та, зокрема, з Конвенцією про права осіб з інвалідністю та підходом, орієнтованим на відновлення.
more
Washington, D.C., USA, 23-27 September 2018
Provisional Agenda Item 4.6
CD56/10, Rev. 1 31 August 2018
Original: Spanish
Updated version June 2015
Manual for use in primary care
Despite Pakistan's progress in reducing the number of wild poliovirus type 1 (WPV1) cases to 8 in 2017 and 12 in 2018, 2019 has seen a significant rise in the number of WPV1 cases (41 cases as of July 8 2019). One of the most intractable challenges the Pakistan Polio Eradication Initiative (PEI) is ...facing is refusals by parents and caregivers to immunise their children with the polio vaccine. In light of this challenge, the Pakistan programme has revisited its strategy and put forward this Extension of the National Emergency Action Plan 2018/2019 (NEAP), which will carry the programme forward from July to December 2019
more
The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world.
In addition, this edition includes summary and recommendations from the virtual meeting of the members of the WHO Programme f...or International Drug Monitoring (PIDM) and other partners, which was held on 20 October 2022.
more
- Conference summary report
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi...th severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19.
more